PTJ
CLYM

Paul Tudor Jones’s Climb Bio CLYM Stock Holding History

Paul Tudor Jones’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,466
Closed -$80.7K – 2885
2024
Q1 		$80.7K Sell
29,466
-24
-0.1% -$66 ﹤0.01% 2104
2023
Q4 		$79.6K Sell
29,490
-214
-0.7% -$557 ﹤0.01% 2255
2023
Q3 		$78.1K Sell
29,704
-2
-0% -$5 ﹤0.01% 2164
2023
Q2 		$83.2K Hold
29,706
– – ﹤0.01% 2305
2023
Q1 		$86K Sell
29,706
-901
-3% -$3.1K ﹤0.01% 2269
2022
Q4 		$112K Sell
30,607
-12
-0% -$36 ﹤0.01% 2213
2022
Q3 		$99K Hold
30,619
– – ﹤0.01% 2154
2022
Q2 		$92K Sell
30,619
-15,473
-34% -$73.2K ﹤0.01% 1929
2022
Q1 		$387K Sell
46,092
-149,366
-76% -$1.39M 0.01% 1415
2021
Q4 		$2.04M Sell
195,458
-91,836
-32% -$1.37M 0.03% 613
2021
Q3 		$5.17M Buy
+287,294
New +$5.94M 0.08% 258

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paul Tudor Jones's CLYM Position: Q2 2024 in Review

Paul Tudor Jones sold out of Climb Bio (CLYM) in Q2 2024, closing a stake of 29,466 shares — an estimated $80.7K sold.

Paul Tudor Jones first reported a position in CLYM in Q3 2021 and held it in 11 quarters. The position peaked at $5.17M in Q3 2021. 47 funds tracked by Wall St. Rank hold CLYM as of Q2 2024.

  • Paul Tudor Jones reported no remaining Climb Bio position as of Q2 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 29,466 Climb Bio shares in Q2 2024, an estimated $80.7K.
  • Paul Tudor Jones first reported a position in Climb Bio in Q3 2021 and held it in 11 quarters.
  • Paul Tudor Jones's Climb Bio position peaked at $5.17M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Climb Bio as of Q2 2024.

Based on Tudor Investment Corp's 13F filing for Q2 2024, filed 14 Aug 2024.